COCH

Envoy Medical is not a company with a stock valuation problem — it is a clinical-stage device developer whose commercial existence is entirely contingent on a future FDA decision. FY2025 revenue was just $241K (from the legacy, commercially-failed Esteem implant that the filing concedes 'failed to gain commercial traction, primarily due to a lack of reimbursement'), against a $23.8M net loss and a -$22.3M operating loss. The derived operating margin of -9,240% and P/S of ~240x are effectively meaningless multiples — there is no business to value on fundamentals, only an option on the fully-implanted Acclaim cochlear implant. Five years of history (net losses of $0.25M → $15.9M → $29.9M → $20.8M → $23.8M) show sustained cash destruction with no revenue inflection.

The balance sheet is the disqualifier. Cash fell 31.8% to $3.74M while operating cash flow was -$18.2M — on that burn rate the company has only a few months of runway and must raise capital imminently. Stockholders' equity is already negative at -$12.2M, liabilities-to-equity is -1.67x, and shares outstanding ballooned 260.5% to 76.9M, evidencing that survival to date has depended on heavy, value-destructive dilution. Accumulated deficit stands at -$313M. Any investor buying today is near-certain to be diluted further, likely at or below the current $0.75 price. Curiously, the company even paid $1.82M in dividends while insolvent and cash-starved — a poor capital-allocation signal.